Core Viewpoint - Mengke Pharmaceutical's stock price has declined significantly, currently trading at 7.27 yuan, representing a drop of 7.03%, and is in a state of loss since its IPO [1] Group 1: Company Overview - Mengke Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 5, 2022, with an initial public offering (IPO) of 13 million shares at a price of 8.16 yuan per share [1] - The stock reached a peak price of 14.20 yuan on its first trading day, which remains the highest price since its listing [1] Group 2: Financial Performance - The total amount raised from the IPO was 1.0608 billion yuan, with a net amount of 959.7279 million yuan after deducting issuance costs [1] - The net amount raised was 290.1495 million yuan less than the original plan of 1.2498774 billion yuan, which was intended for innovative drug research and development, marketing channel upgrades, academic promotion projects, and working capital [1] - The total issuance costs amounted to 101.0721 million yuan, with underwriting and sponsorship fees accounting for 79.0296 million yuan [1]
盟科药业跌7.03% 2022年上市即巅峰募10.6亿元